Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

BACKGROUND: The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase II...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Target Oncol
Hauptverfasser: Gupta, Neeraj, Yang, Huyuan, Hanley, Michael J., Zhang, Steven, Liu, Rachael, Kumar, Shaji, Richardson, Paul G., Skacel, Tomas, Venkatakrishnan, Karthik
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2017
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5610674/
https://ncbi.nlm.nih.gov/pubmed/28803351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0524-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge